Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Gross Profit | -740,000 | 1235% |
| Cost of Revenue | 740,000 | 0% |
| Operating expense | 22M | 99.9% |
| Net Income | -24M | 19.4% |
| EBITDA | -23M | 99.9% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 68M | 21.8% |
| Total Liabilities | 40M | 10.2% |
| Total Equity | 29M | 44.3% |
| Shares Outstanding | 39M | 43% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -20.8B | 22.6% |
| Cash from investing | 5.28B | 10306.3% |
| Cash from financing | -35M | 3483.2% |
EPS
Financial Highlights for Inovio Pharmaceuticals in Q2 '25
Gross Profit stood at -740,000, marking a -1235% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 740,000, a 0% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 22M, showing a -99.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -24M, showing a -19.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -23M, showing a 99.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Inovio Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
